Abstract Purpose: NY-ESO-1 belongs to a class of cancer/testis antigens and has been shown to be immunogenic in cancer patients.We synthesized a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein (CHP/ESO) and investigated the in vitro stimulation of CD8 and CD4 T cells from peripheral blood mononuclear cells in healthy donors with autologous CHP/ESO-loaded dendritic cells as antigen-presenting cells. Experimental Design: In vitro stimulation of CD8 or CD4 T cells was determined by IFNg ELISPOT assays against autologous EBV-B cells infected with vaccinia/NY-ESO-1 recombinant virus or wild-type vaccinia virus as targets and by ELISA measuring secreted IFNg. Results: NY-ESO-1^specific CD8 and CD4 T cells were induced. In a donor expressing HLA-A2, CD8 T cells stimulated with CHP/ESO-loaded dendritic cells recognized naturally processed NY-ESO-1 157-165 , an HLA-A2^binding CD8 T cell epitope. NY-ESO-1CD4 T cells wereTh1-type. We identified a new HLA-DR15^binding CD4 Tcell epitope, NY-ESO-1 37-50 . Conclusions: These findings indicate that CHP/ESO is a promising polyvalent cancer vaccine targeting NY-ESO-1.
NY-ESO-1 was originally identified by serologic expression cloning (SEREX) using serum from a patient with esophageal cancer, and exhibited characteristics of cancer/testis antigens whose expression is observed in various types of cancer and germ tissues such as testis, ovary, and placenta, but not in normal somatic tissues (1) . The antibody response to NY-ESO-1 is much more frequent than other human tumor antigens in patients with cancer (2) , and CD8 T cell response to NY-ESO-1 is mostly associated with the humoral immune response to NY-ESO-1 (3, 4) , suggesting that NY-ESO-1 is a highly immunogenic human tumor antigen.
CD8 T cell epitopes from NY-ESO-1 have been identified for several MHC class I alleles such as HLA-A*0201 (5), A*2402 (6) , and A*3101 (7) . The CD8 T cell response was found to be polyclonal in patients with NY-ESO-1 antibody (8) . Simultaneous HLA-A2-and HLA-Cw3 -restricted CD8 T cell responses were elicited in a malignant melanoma patient with NY-ESO-1 antibody (8) . CD4 T cell responses to NY-ESO-1 have been described and many epitopes binding to several HLA-DR alleles have been identified, including a promiscuous one (9 -12) . HLA-DP4 -restricted CD4 T cell response was correlated with antibody response to NY-ESO-1 in patients with cancer (13, 14) . Those studies showed that NY-ESO-1 contains multiple T cell epitopes and that polyvalent vaccine using full-length protein, rather than monovalent vaccine using peptides, is likely to evoke strong immunity against NY-ESO-1, and to induce anticancer effects on tumors expressing NY-ESO-1. However, exogenous protein antigens hardly sensitize CD8 T cells because they are internalized into endosomes and processed mainly by the class II pathway. Immature dendritic cells (DC) were reported to differentiate into mature type DCs after phagocytosis of NY-ESO-1/IgG immune complex, and was shown to present an HLA-A2 -binding CD8 T cell epitope (15) . NY-ESO-1 formulated with ISCOMATRIX, a 40 nm cage-like structure composed of saponin, phospholipids, and cholesterol was taken up by DCs, which cross-presented a CD8 T cell epitope (16) . Polyclonal CD8-and CD4-T cell responses were observed in patients immunized with NY-ESO-1/ISCOMATRIX (17) . These findings indicated that exogenous protein antigens could be cross-presented and sensitize CD8 T cells when appropriate delivery systems were used.
Cholesterol-bearing hydrophobized pullulan (CHP) is composed of a pullulan backbone and cholesterol branches, and forms colloidally stable nanoparticles in water by selfassociation because of the formation of cross-linking domains through the interaction of the cholesterol branches. CHP nanoparticles form complexes with soluble protein (18) . Immunization of mice with HER2 protein complexed with CHP (CHP/HER2) induced antibody and CD8 T cell responses to HER2 (19) . DCs treated with CHP/HER2 crosspresented the antigenic peptide, HER2 63-71 , on HLA-A24 (20) . In the present study, we synthesized a complex of CHP and NY-ESO-1 protein (CHP/ESO) and successfully induced NY-ESO-1 -specific CD8 and CD4 T cells by in vitro stimulation with autologous CHP/ESO-loaded DCs. In addition, we identified a new HLA-DR15 -binding CD4 T cell epitope from NY-ESO-1.
Materials and Methods
Cell lines. SK-MEL-37 is a melanoma cell line expressing NY-ESO-1 mRNA and HLA-A*0201. SK-MEL-23 is a melanoma cell line expressing HLA-A * 0201, but not NY-ESO-1 mRNA. Antibodies. Anti-human CD4, anti-human CD8, anti-HLA class I, anti-HLA class II, anti-DP, anti-DQ, and anti-DR monoclonal antibodies (mAb) were purchased from BD Bioscience (San Jose, CA). Antihuman IFNg mAb (1-DIK) was obtained from Mabtech (Stockholm, Sweden). Rabbit anti-human IFNg serum was obtained by immunizing a rabbit with recombinant human IFNg protein. Goat anti-rabbit IgG serum conjugated with alkaline-phosphatase and goat anti-rabbit IgG serum conjugated with horseradish peroxidase were purchased from Southern Biotechnology (Birmingham, AL) and MBL (Nagoya, Japan), respectively.
Cytokines. Human recombinant granulocyte macrophage colonystimulating factor and interleukin (IL)-2 were kindly provided by Kirin (Tokyo, Japan) and Takeda (Osaka, Japan) pharmaceutical companies, respectively. Human recombinant IL-4 was purchased from Peprotech (London, England).
Peptides. All peptides were synthesized by standard solid-phase methods using N-(9-fluorenyl) methoxycarbonyl (Fmoc) chemistry and a peptide synthesizer (AMS422; ABIMED, Langenfeld, Germany).
Recombinant proteins and CHP/ESO complex. Recombinant NY-ESO-1 and SSX2 proteins were prepared as described previously (1, 2) . The CHP/ESO complex was synthesized as described previously (18) . ) were cultured in six-well plates in the medium supplemented with 10 ng/mL IL-4 and 10 ng/mL granulocyte macrophage colony-stimulating factor for 7 days at 37jC in a 5% CO 2 atmosphere. The medium used was RPMI 1640 with 5% human AB sera, 2 mmol/L L-glutamine, 100 units/mL penicillin, 100 Ag/mL streptomycin, and 1% nonessential amino acids. Flow cytometric analysis showed that these DCs displayed an immature phenotype (CD80 ) were cultured with CHP/ESO (20 Ag/mL CHP and 1 Ag/mL NY-ESO-1 protein) for 3 hours at 37jC in a 5% CO 2 atmosphere. After incubation, DCs were washed with RPMI 1640 and cultured in the medium supplemented with IL-4 and granulocyte macrophage colonystimulating factor for 18 hours at 37jC in a 5% CO 2 atmosphere and then used as stimulators.
In vitro stimulation of CD8 and CD4 T cells with DCs. CD8 and CD4 T cells were purified from PBMC using antibody-coated magnetic beads (Miltenyi Biotec). Two million purified T cells were cocultured with 5 Â 5 DCs were pulsed with various concentrations of peptides in 1 mL of X-VIVO 15 for 1 hour at 37jC in a 5% CO 2 atmosphere. Peptide-pulsed EBV-B cells were used as target cells after irradiation.
IFNg ELISPOT assay. This method has been described previously (4) . IFNg ELISA assay. Responding CD8 T cells (2 Â 10 4 /well) and target cells were cultured in 96-well round-bottomed plates (Falcon, Franklin Lakes, NJ) for 20 hours at 37jC in X-VIVO 15 medium. For antibody blocking, 2.5 Ag/mL mAbs were present throughout the assays. Culture supernatants were transferred to ELISA plates (Nunc, Rochester, NY) precoated with 2 Ag/mL anti-human IFNg mAb and incubated for 2 hours at 37jC. The plates were then washed and rabbit anti-human IFNg serum diluted at 1:800 with PBS was added and incubated for 2 hours at 37jC. After the plates were washed extensively, goat anti-rabbit IgG serum conjugated with horseradish peroxidase diluted 1:2,000 was added and incubated for 1 hour at 37jC. After washing, the substrate solution [50 mmol/L citric acid, 100 mmol/L Na 2 HPO 4 , 0.03% orthophenylenediamine, 0.1% H 2 O 2 in distilled water (pH 5.0)] was added to each well and incubated for 15 minutes at room temperature. After adding 6 N H 2 SO 4 , the plates were read using a U-2001 spectrophotometer (Tosoh, Tokyo, Japan).
Statistical analysis. The values were expressed as means F SD. Unpaired Student's t test was used.
Results
In vitro stimulation of CD8 T cells with CHP/ESO-loaded DCs. We investigated the in vitro stimulation of CD8 T cells after purification of those cells from PBMC of a healthy donor carrying HLA-A*0201 (HD1, see Table 1 The production of IFNg by those HD1 CD8-T cells against autologous EBV-B cells pulsed with NY-ESO-1 157-165 peptide was blocked by anti-CD8 mAb and anti-HLA class I mAb, but not anti-CD4 mAb or anti-HLA class II mAb (Fig. 2B) . We further investigated the in vitro stimulation of CD8 T cells with CHP/ESO-loaded DCs in three more healthy donors (HD2, HD3, and HD4). As shown in Table 1 , NY-ESO-1 -specific CD8 T cells were induced in all four healthy donors including HD1. CD8 T cells induced in HD4 carrying HLA-A*0206, but not in HD2 carrying HLA-A*0203, recognized NY-ESO-1 157-165 peptide (data not shown).
Stimulation of T Cells by CHP/ESO-Loaded
In vitro stimulation of CD4 T cells with CHP/ESO-loaded DCs. We next investigated the in vitro stimulation of CD4 T cells after purification of those cells from PBMC of HD1 with autologous CHP/ESO-loaded DCs twice at a week interval. As shown in Fig. 3A, As shown in Fig. 3C , production of IFNg ELISPOTs by those HD1 CD4 T cells against EBV-B cells infected with v.v. ESO was blocked by anti-CD4 mAb, anti-HLA class II mAb and anti-HLA-DR mAb, but not anti-CD8 mAb, anti-HLA class I mAb, anti-DP mAb, or anti-DQ mAb.
We evaluated the in vitro stimulation of CD4 T cells by CHP/ ESO-loaded DCs in two more healthy donors. As shown in Table 2 , NY-ESO-1 -specific CD4 T cells were induced in all three healthy donors including HD1. No IL-4 was detected in the culture, indicating that those CD4 T cells were Th1 type (data not shown).
Identification of an HLA-DR15 -binding CD4 T cell epitope from NY-ESO-1. Twenty-eight 18-mer peptides of NY-ESO-1 with 12 overlapping residues were synthesized to identify the epitope recognized by HD1 CD4 T cells. The production of IFNg ELISPOTs by HD1 CD4 T cells (2 Â 10 4 ) stimulated with autologous CHP/ESO-loaded DCs was determined against autologous EBV-B cells (2 Â 10 4 ) pulsed with each peptide at a concentration of 10 À5 mol/L. As shown in Fig. 4A and B, production of IFNg ELISPOTs was observed against autologous EBV-B cells pulsed with peptide no. 7 (NY-ESO-1 37-54 , AGAT-GGRGPRGAGAARAS) at concentrations as low as 1 Â 10 À7 mol/L. The production of IFNg ELISPOTs by HD1 CD4 T cells against NY-ESO-1 37-54 -pulsed autologous EBV-B cells was significantly blocked by anti-HLA-DR mAb (data not shown), indicating that the peptide was recognized in association with HLA-DR. To investigate the restriction molecule, autologous and allogeneic EBV-B cells were used as target cells. As shown in Table 3 , NY-ESO-1 37-54 peptide-pulsed EBV-B cells derived from HLA-DR*1502 -positive individuals were recognized. Furthermore, CD4 T cells from an HLA-DR*1502 -positive individuals were stimulated in vitro with the peptide (Fig. 4C) . To define the minimal sequence, we synthesized peptides truncated at either the NH 2 or COOH terminus of NY-ESO-1 37-54 and analyzed HD1 CD4 T cell recognition of these peptides. As shown in Fig. 5 , truncation at the COOH terminus of the first four amino acids did not affect recognition. Further truncation of the peptide at the COOH terminus resulted in decreased peptide recognition. Truncation of the first amino acid at the NH 2 terminus caused loss of recognition. Thus, it was determined that NY-ESO-1 37-50 was the minimal epitope recognized by CD4 T cells binding to HLA-DR15.
Discussion
NY-ESO-1 is one of a few tumor antigens which elicit simultaneous humoral and cellular immune responses spontaneously (3, 4) and after vaccination (17, 21) Mature DCs have the capacity to process and present exogenous protein antigens on MHC class I molecules through cross-presentation (22, 23) . Loading DCs with CHP/ESO neither up-regulated costimulatory molecules and CD40 on their surface, nor induced IL-12 production (data not shown), suggesting that DCs loaded with CHP/ESO retained an immature phenotype and cross-presented NY-ESO-1 antigen on MHC class I. CHP nanoparticles form complexes with denatured protein and release complexed proteins in their refolded naïve form upon the addition of cyclodextrin, which disrupts the hydrophobic interaction of cholesterol branches (24, 25) , suggesting that CHP nanoparticles behave like chaperones. Stimulation of CD8 T cells by immature DCs loaded with CHP/ESO, but not NY-ESO-1 protein alone without in vitro treatment for DC maturation, may be attributed to cross-presentation by the chaperone activity of CHP nanoparticles.
DCs internalize exogenous protein antigens into endosomes, process them through the class II pathway, and then present antigenic peptides on MHC class II protein. In this study, we showed that CD4 T cells were stimulated in vitro with CHP/ ESO-loaded DCs without treatment to induce maturation as efficiently as the protein-loaded mature DCs with lipopolysaccharide treatment. No stimulation of CD4 T cells was observed with NY-ESO-1 protein -loaded DCs without lipopolysaccharide treatment. Those CD4 T cells produced a large amount of IFNg, but no IL-4, in three healthy donors, indicating that they were Th1 type, which may create an environment favoring CD8 T cell stimulation. The major advantage of using a full-length protein with an appropriate delivery system for a cancer vaccine is to induce multiple CD8 and CD4 T cell responses. In this regard, CHP/ESO represents one of the valuable candidates for a polyvalent cancer vaccine.
We identified a new HLA-DR15 -binding CD4 T cell epitope from NY-ESO-1. We repeatedly observed weak CD4 T cell responses to several NY-ESO-1 peptides located in the COOH terminus. However, a high concentration 10 À5 mol/L was required for their recognition by NY-ESO-1 CD4 T cells. In contrast, NY-ESO-1 37-54 was recognized at a concentration as low as 10 À7 mol/L. EBV-B cells expressing HLA-DR15 alone could present NY-ESO-1 37-54 . Truncation of the peptide revealed that NY-ESO-1 37-50 was the minimal peptide sequence required.
In conclusion, this study showed that CHP/ESO-loaded DCs efficiently stimulated both CD8 and CD4 T cells in vitro and, therefore suggested that CHP/ESO is a promising polyvalent vaccine for immunotherapy targeting NY-ESO-1. We are conducting a phase I clinical trial of CHP/ESO vaccination in patients with cancer expressing NY-ESO-1. It will be important to monitor which types of immune responses, humoral, or cellular, are mainly evoked and to see whether immune responses have some effect on the disease status of vaccinated cancer patients. Preliminary findings suggested that T cell responses as well as antibody responses occurred after vaccination. 
